Global health agency says 9.5 million people were living with the condition in 2025, as millions continue to struggle to access affordable insulin and essential care.
By Bunmi Yekini
The World Health Organization (WHO) has issued its first-ever guidelines on the diagnosis and management of type 1 diabetes in adults, seeking to improve access to essential treatment and care, particularly in countries with limited health resources.
The guidelines, released to mark World Diabetes Day 2026, provide evidence-based recommendations for managing the lifelong condition across different healthcare settings, including emergency and humanitarian situations.
Type 1 diabetes occurs when the body does not produce enough insulin, a hormone needed to regulate blood glucose levels. People living with the condition depend on daily insulin treatment to survive.
Despite the discovery of insulin more than a century ago, access to affordable, quality insulin remains a challenge for many patients worldwide.
WHO estimates that about 9.5 million people were living with type 1 diabetes globally in 2025, with a further 500,000 people diagnosed during the year.
Although the condition has traditionally been associated with children, the health agency says it is increasingly affecting adults.
“Insulin is a lifesaving treatment, discovered more than 100 years ago. Yet many people with type 1 diabetes do not have access to affordable and high-quality insulin,” said Dr Søren Brostrøm, WHO Director of Noncommunicable Diseases and Mental Health.
He said the new guidelines would help countries provide appropriate care, including in settings where healthcare resources are limited or services have been disrupted.
Under the recommendations, people with type 1 diabetes should receive insulin injections several times daily, with doses adjusted according to their blood glucose levels.
WHO identifies human insulin, a manufactured form that works like the insulin naturally produced by the body, as an effective treatment option, while noting that other types of insulin may be used when necessary.
The guidelines also emphasise regular blood glucose monitoring to help patients and healthcare providers manage the condition.
Monitoring options include laboratory tests that measure average blood glucose levels over several months, finger-prick tests and continuous glucose monitoring devices, which use small sensors worn on the skin.
Where blood glucose testing is unavailable, WHO says urine glucose testing may be considered.
The recommendations are expected to support the agency’s target of ensuring that everyone living with type 1 diabetes has access to affordable insulin treatment and blood glucose self-monitoring by 2030.
WHO said it would support countries in implementing the guidelines through practical tools and guidance to monitor progress.
It also urged governments to involve people living with type 1 diabetes in designing, implementing and evaluating national diabetes programmes.
The 2026 World Diabetes Day campaign, themed “Early action on diabetes”, draws attention to the importance of timely diagnosis and treatment in reducing the risk of complications.
Diabetes can lead to serious health problems, including blindness, kidney failure, heart attacks, stroke and lower-limb amputation.
The global burden of the disease has more than quadrupled since 1990. In 2022, an estimated 830 million people were living with diabetes worldwide, most of them with type 2 diabetes.
WHO also estimates that more than 40% of people with diabetes are unaware they have the condition, leaving them undiagnosed and potentially without the care they need.
